Endothelial cell capture of heparin-binding growth factors under flow.
Circulation is an important delivery method for both natural and synthetic molecules, but microenvironment interactions, regulated by endothelial cells and critical to the molecule's fate, are difficult to interpret using traditional approaches. In this work, we analyzed and predicted growth factor capture under flow using computer modeling and a three-dimensional experimental approach that includes pertinent circulation characteristics such as pulsatile flow, competing binding interactions, and limited bioavailability. An understanding of the controlling features of this process was desired. The experimental module consisted of a bioreactor with synthetic endothelial-lined hollow fibers under flow. The physical design of the system was incorporated into the model parameters. The heparin-binding growth factor fibroblast growth factor-2 (FGF-2) was used for both the experiments and simulations. Our computational model was composed of three parts: (1) media flow equations, (2) mass transport equations and (3) cell surface reaction equations. The model is based on the flow and reactions within a single hollow fiber and was scaled linearly by the total number of fibers for comparison with experimental results. Our model predicted, and experiments confirmed, that removal of heparan sulfate (HS) from the system would result in a dramatic loss of binding by heparin-binding proteins, but not by proteins that do not bind heparin. The model further predicted a significant loss of bound protein at flow rates only slightly higher than average capillary flow rates, corroborated experimentally, suggesting that the probability of capture in a single pass at high flow rates is extremely low. Several other key parameters were investigated with the coupling between receptors and proteoglycans shown to have a critical impact on successful capture. The combined system offers opportunities to examine circulation capture in a straightforward quantitative manner that should prove advantageous for biologicals or drug delivery investigations.
Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States of America.
Bing
B
Zhao
Changjiang
C
Zhang
Kimberly
K
Forsten-Williams
Jun
J
Zhang
Michael
M
Fannon
D000818:Animals; D019149:Bioreactors; D002417:Cattle; D002462:Cell Membrane / Q000378:metabolism*; D002478:Cells, Cultured; D019295:Computational Biology; D003198:Computer Simulation; D042783:Endothelial Cells / Q000378:metabolism*; D004815:Epidermal Growth Factor / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism*; D019763:Heparin Lyase; D008955:Models, Cardiovascular; D011485:Protein Binding; D011509:Proteoglycans; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D012212:Rheology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D019812:Heparan Sulfate Proteoglycans; D011509:Proteoglycans; D017468:Receptors, Fibroblast Growth Factor; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D019763:Heparin Lyase